Geoff Meacham



Geoff Meacham Recent News

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
BofA Downgrades CureVac On Limited 2022 Prospects
BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
How To Play Moderna Stock Ahead Of Key FDA COVID-19 Booster Shot Ruling
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
Moderna Analysts Debate Need For Biopharma's COVID-19 Booster Shot
Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA
Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst
Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
These 3 New Biotechs Have Differentiated Platforms, Technology: BofA
Should Investors Be Worried About The Delta Strain Of COVID-19?
Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug
Why BofA Is Bearish On Moderna Despite COVID-19 Vaccine Success
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Why This Pfizer Analyst Is Sidelined After Beat-And-Raise Q1
Inovio Has 'Bigger Value Drivers' Outside Of COVID-19 Vaccine Program: BofA Analyst
Moderna Analyst: Unrealistic COVID-19 Vaccine Expectations Create Unfavorable Setup
Moderna Analyst Questions Whether COVID-19 Opportunity Can Support Valuation
Pfizer Analyst: Coronavirus Vaccine Moving Closer To Emergency Use Authorization